Higher German Drug Prices Could Reduce Medicaid MFN Savings
Higher German drug prices could reduce Medicaid's extra MFN rebates if they lift its international benchmark. The effect depends on price data and contract terms.
Primary lensTrade policy
Sub-topicPolicy monitoring
Evidence base8 records used
Use casePolicy monitoring
Washington is pressing Germany to pay more for medicines while extending a U.S. payment model that uses German prices to calculate Medicaid rebates. In PhRMA's filed summary for USTR's September 22 Germany drug-pricing hearing, the industry group seeks a binding agreement that narrows the countries' spending gap on innovative medicines and requires German policy reforms. Four days before the hearing, CMS announced broader state participation in GENEROUS, Medicaid's voluntary most-favored-nation pricing model.
A German pricing concession could reduce the additional savings available under that model. Under , a higher German net price can raise the international benchmark used to calculate supplemental rebates. The effect depends on Germany's position in the price ranking, the reporting period and the contract. It is not an estimate of savings already lost.
For pharmaceutical trade counsel assessing a proposed German settlement, higher manufacturer receipts in Germany cannot double as proof of lower U.S. spending. The settlement assessment needs to show how the same concession would pass through the Medicaid formula.
The Second-Lowest Price Does the Work
GENEROUS does not simply import the lowest advertised foreign price. The state request for applications, page 7, specifies the second-lowest country-specific manufacturer-reported net price among eight countries, including Germany. Prices reflect all rebates, discounts and other manufacturer concessions, then undergo a GDP-per-capita adjustment using purchasing power parity.
That ranking limits the German effect. A higher German price changes the benchmark only when it changes the second-lowest value. Raising a price already above that point leaves the benchmark unchanged, assuming the other countries' prices and adjustments stay fixed.
The examples below use invented, already-adjusted price units for one matched drug. The seven other countries' prices remain 40, 60, 80, 100, 120, 140 and 160. These are arithmetic illustrations, not observed drug prices.
German price change
Position after the increase
Second-lowest benchmark
30 to 35
Still lowest
Unchanged at 40
30 to 50
Moves from lowest to second-lowest
Rises from 40 to 50
50 to 70
Moves from second-lowest to third-lowest
Rises from 50 to 60
A country need not remain the benchmark country to move the benchmark. In the last example, Germany's increase hands that role to another country at a higher price. Conversely, a rise in the lowest German price does nothing until it crosses the next price. A German percentage increase alone cannot establish the Medicaid effect.
German Revenue and Medicaid Savings Need Separate Calculations
GENEROUS translates its reference price into a guaranteed net unit price for a covered drug. Under the state RFA's rebate formula, page 18, the supplemental rebate equals wholesale acquisition cost minus the sum of that guaranteed price and the statutory Medicaid unit rebate amount. Holding the other inputs constant, a higher guaranteed price reduces the supplemental rebate where one is payable.
The comparison is with the rebate that would have applied if German prices had stayed unchanged. Medicaid could still save money relative to its previous arrangements. The mechanism also leaves statutory Medicaid rebates intact, as the state RFA explains on page 6. A smaller additional rebate is not evidence that every U.S. drug price rises.
Nor can the German statutory rebate headline serve as the input. Traverse's analysis of Germany's fixed pharma rebate and USTR's Section 301 proof explains why product coverage and reimbursement agreements change its incidence. The Medicaid calculation requires the relevant drug's average net price for the reporting period, after the full set of concessions. A change in a nominal reimbursement amount may therefore differ from the change CMS measures.
USTR is also examining Germany's conditions for keeping reimbursement prices confidential. Public availability is a separate question from the price data used by GENEROUS. Participating manufacturers report international net prices directly to CMS. The manufacturer RFA, section 5.2, also provides protection for confidential commercial information. A price unavailable to outside analysts is not, for that reason, unavailable to CMS. Counsel needs the reportable net-price calculation, not an inference drawn from a missing public price.
The Reporting Calendar Delays Transmission
Even a German increase that changes the ranking does not immediately reset a state's rebate. The state RFA, page 18, uses April 1, 2025, through March 31, 2026, as the international price reporting period for model year 2027. For model year 2028, the window advances to April 1, 2026, through March 31, 2027.
For illustration, a German concession taking effect on January 1, 2027 would, under that schedule, fall outside the 2027 model-year window. It would enter only the last three months of the reporting window for 2028, with its contribution to the average depending on the underlying transactions. States may implement the resulting prices during the applicable model year according to their preferred-drug-list schedules. The published design guarantees the price for at least 12 months from the supplemental rebate agreement's effective date.
These are the terms of the published design. The RFA expressly cautions on page 4 that finalized participation agreements may differ. The actual agreement and its renewal provisions control the assessment of an individual manufacturer's exposure.
Participation is another limit. CMS reported on September 18 that all 50 states, the District of Columbia and Puerto Rico had applied, while 40 states and Puerto Rico had signed. Remaining states have until September 30 to sign. The current CMS model page confirms that states choose the individual drugs for which to obtain model pricing. National application figures therefore cannot establish the volume of drug purchases exposed to a German price change.
The Rebuttal Record Needs a Price Comparison
The Section 301 proceeding still offers a place to test this interaction. USTR's June initiation notice allows comments rebutting or supplementing hearing testimony within seven calendar days after the final hearing day. That would be September 29 if the hearing concluded on September 22. The Traverse Policy Signal for USTR's Germany Section 301 initiation notice links the underlying procedural record.
A useful settlement assessment would compare the affected drugs under unchanged German pricing and under the proposed concession. It would identify the price component Germany would change, the resulting reportable net price and its adjusted rank. The relevant reporting window and existing U.S. price guarantee would then show when any difference could reach a state's supplemental rebate.
Claims about total U.S. savings require the participating manufacturers, drugs, states and utilization as well. Without those inputs, the record supports a directional result, not a dollar forecast.
Counsel can quantify the effect once those inputs are available and a proposed German pricing commitment can be matched to the drug's CMS reporting period and executed rebate agreement, including whether and when its guaranteed price can reset.
From reading to review
Run the numbers on your lane.
The duty calculator runs the current stack for any HTS code and origin. A free account opens full tool output, AD/CVD detail, Chapter 98 processing, and available exports.